FDA Sets Regulatory Review Period for VYALEV Patent Extension Request
June 30, 2026
June 30, 2026
WASHINGTON, June 30 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration determined VYALEV's regulatory review lasted 2,871 days, advancing patent extension proceedings before the U.S. Patent and Trademark Office.
The Food and Drug Administration has determined that the regulatory review period for Parkinson's disease treatment VYALEV lasted 2,871 days, a key step in evaluating requests to extend patents covering the drug under federal p . . .
The Food and Drug Administration has determined that the regulatory review period for Parkinson's disease treatment VYALEV lasted 2,871 days, a key step in evaluating requests to extend patents covering the drug under federal p . . .